Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Abstract Background they remained within the normal range in all cases, and improved in the two acute cases treated with high-dose steroids The clinical outcome was comparable to the reported cases occurring in non-immunosuppressed subjects Conclusion Patients under immunosuppressive therapy for AIH developing COVID-19 show a disease course presumptively similar to that reported in non-immunosuppressed population These data might help medical decision when dealing with SARS-CoV-2 infection in immunocompromised patients